MTOR and pancreatic neoplasm: Cancers with Tier II variants included bladder cancer, breast cancer, NSCLC, pancreatic cancer and sarcoma [45, 58], and up to 76% of recurrent/metastatic cancer patients with Tier II variants received PI3K‐Akt–mTOR therapies through clinical trials [50].